Month: May 2025

– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million and UDENYCA net revenue, now reflected in discontinued operations, was $31.5 million in Q1 2025  – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2025...

Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025 FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional details on the accelerated pathway are expected in mid-2025 after our planned Type B meeting with the FDA Ended the first quarter with $328.5 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027WINSTON-SALEM, N.C., May 12, 2025 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported financial results and business highlights for the first quarter ended March 31, 2025. “The next two quarters are important for ProKidney as we approach...

Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver (EASL) Congress 2025 Virtual Investor Event with Key Opinion Leader Insights on HCV to be Held May 14, 2025, at 10:00 AM ET BOSTON, May 12, 2025 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. The Company’s combination regimen of bemnifosbuvir (BEM), a nucleotide...

Reports Net Loss of $17.6 Million or $0.40 per Diluted Share, and Adjusted EBITDA of ($16.1) Million CLAYTON, Mo., May 12, 2025 (GLOBE NEWSWIRE) — FutureFuel Corp. (NYSE: FF) (“FutureFuel”), a manufacturer of custom and performance chemicals and biofuels, today announced financial results for the first quarter ended March 31, 2025. First quarter 2025 Financial Highlights (all comparisons are with the first quarter of 2024)Revenues were $17.5 million, a decrease of 70% or $40.7 million compared to $58.3 million. Net loss was $17.6 million, or $0.40 per diluted share, down from a net income of $4.3 million, or $0.10 per diluted share. Adjusted EBITDA(1) was ($16.1) million, down from $7.1 million.(1)  A non-GAAP financial measure.  See “Non-GAAP Financial Measures” for a description of the measure and a reconciliation to the...

Midland, Texas, May 12, 2025 (GLOBE NEWSWIRE) — Natural Gas Services Group, Inc. (“NGS” or the “Company”) (NYSE:NGS), a leading provider of natural gas compression equipment, technology, and services to the energy industry, today announced financial results for the three months ended March 31, 2025. The Company also raised the high-end of its full-year 2025 Adjusted EBITDA guidance to $79 million, citing continued strength in its business and growing demand across its fleet. First Quarter 2025 HighlightsRental revenue of $38.9 million for the first quarter of 2025 representing a 15% year-over-year increase and a 2% sequential increase compared to the period ended December 31, 2024.Net income of $4.9 million or $0.38 per diluted share for the first quarter of 2025 compared to net income of $5.1 million or $0.41 per diluted...

Q1 Revenue Growth of 0.8%, Currency Neutral Growth of 2.6% Q1 Annual Subscription Revenue Growth of 5.4%, Currency Neutral 7.2% Annual Subscription Revenue Rose to 57.2% of Total Revenue in Q1 Updates 2025 Guidance to Reflect FX Impacts, while Reaffirming Currency Neutral Revenue Growth OutlookNEW YORK, May 12, 2025 (GLOBE NEWSWIRE) — Getty Images Holdings, Inc. (“Getty Images” or the “Company”) (NYSE: GETY), a preeminent global visual content creator and marketplace, today reported financial results for the first quarter ended March 31, 2025. “Results in the first quarter were consistent with our expectations, with growth highlighted by gains across our subscription business, and continued customer value delivered through our offerings,” said Craig Peters, Chief Executive Officer for Getty Images. “We remain committed to investing...

First Quarter 2025 Revenue of $36.0 million; Highest Q1 in History OMAHA, Neb., May 12, 2025 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus”), a leading self-custodial cryptocurrency platform, today announced its unaudited results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights (Unaudited)       In USD millions, except percentages Q1 2025 Q1 2024  % Change                   Revenue $ 36.0   $ 29.1     24 %                   Technology, development and user support   14.9     10.7     39 %                   General and administrative   14.3     8.0     79 %                   Loss (gain) on digital assets, net   28.8     (56.8 )   (151 %)                   Net (loss) income   (12.9 )   54.8     (124 %)                   “Exodus...

SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Highlights:Quarterly revenue of $46.9 million, Net loss of $(52.9) million (including a goodwill impairment of $12.4 million), and Adjusted EBITDA of $(10.5) million; and Revenue for the full year 2025 is expected to be in the range of $185.0 million to $205.0 million, unchanged from previous guidance.“Our first quarter revenue exceeded our guidance range, and our base business, which excludes revenue from high-volume CleanCap® for commercial vaccine programs, grew more than $4 million compared...